Women's Genome Health Study
early-onset atrial fibrillation
The Women’s Genome Health Study is a prospective cohort for genome-wide genetic analysis derived from the Women’s Health Study that was a balanced 2x2 factorial placebo-controled trial of aspirin (100mg every other day) and vitamin E (600 IU every other day) over 10 years beginning 1992-1994 for primary prevention of CVD and cancer among 39,876 female health care professionals, 45 years old and free of known prevalent endpoint conditions at baseline. Approximately 28,346 WHS participants provided a baseline blood sample within which cardiovascular risk factors biomarkers were measured and DNA was extracted for genotyping. Demographic and lifestyle data were collected by questionnaire. Follow-up was by annual questionnaire. Since the conclusion of the trial period, the cohort has continued for observational follow-up.